Entod Pharmaceuticals’ innovative eye drops, PresVu, have received approval from the Drugs Controller General of India (DCGI). This marks a significant advancement, as PresVu becomes the first eye drop in India specifically designed for treating presbyopia, a common vision issue among individuals over 40.
Understanding Presbyopia
Presbyopia is an age-related condition that impairs the ability to focus on close objects. It affects a large portion of the global population, with estimates suggesting that between 1.09 billion and 1.80 billion people suffer from this condition. As people age, their ability to focus on near objects declines, often leading to difficulties in reading and other close-up tasks.
Benefits of PresVu
PresVu offers a notable alternative to traditional reading glasses, contact lenses, or surgical measures. According to Dr. Aditya Sethi, the eye drop improves near vision within 15 minutes, significantly enhancing the quality of life for those affected by presbyopia. The advanced dynamic buffer technology in PresVu adapts quickly to the pH of tears, providing prolonged relief and added eye lubrication.
Expert Insights
Nikhil K Masurkar, CEO of Entod Pharmaceuticals, expressed enthusiasm about the approval, stating, “PresVu represents a significant advancement in eye care. Its approval is a major step in our mission to enhance vision solutions in India.”
Dr. Dhananjay Bakhle also praised PresVu’s approval, highlighting it as a promising development in the field of ophthalmology. For individuals experiencing blurred near vision, consulting with a healthcare provider is recommended to ensure effective treatment and symptom management.
PresVu’s launch is expected to make a substantial impact on managing presbyopia and improving the daily lives of many individuals.
